GenSight Biologics enrolls first subject in first-in-man PIONEER Phase I/II clinical trial of GS030 combining gene therapy and Optogenetics for the treatment of Retinitis Pigmentosa

Ophthalmology Innovation Summit @ AAO, Chicago (IL)

American Academy of Ophthalmology, Chicago (IL)

GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO

ISCAS 2018, Florence, Italy

21st Annual Meeting ASGCT, Chicago (IL), US

ARVO Annual Meeting, Honolulu, Hawaï, US

GenSight Biologics receives MHRA approval to initiate Phase I/II PIONEER clinical trial of GS030 gene therapy in Retinitis Pigmentosa

GenSight Biologics to Present Data on GS010 and GS030 at the 2017 Congress of the European Society of Gene & Cell Therapy

GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO